Acorah Software Products - Accounts Production 19.4.300 false true 31 March 2025 1 April 2024 false 1 April 2025 31 March 2026 31 March 2026 12318994 Mrs L J Edgar iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12318994 2025-03-31 12318994 2026-03-31 12318994 2025-04-01 2026-03-31 12318994 frs-core:CurrentFinancialInstruments 2026-03-31 12318994 frs-core:ShareCapital 2026-03-31 12318994 frs-core:RetainedEarningsAccumulatedLosses 2026-03-31 12318994 frs-bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 12318994 frs-bus:FilletedAccounts 2025-04-01 2026-03-31 12318994 frs-bus:SmallEntities 2025-04-01 2026-03-31 12318994 frs-bus:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 12318994 frs-bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 12318994 frs-core:UnlistedNon-exchangeTraded 2026-03-31 12318994 frs-core:UnlistedNon-exchangeTraded 2025-03-31 12318994 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2025-03-31 12318994 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2026-03-31 12318994 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-03-31 12318994 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2026-03-31 12318994 frs-bus:Director1 2025-04-01 2026-03-31 12318994 frs-countries:EnglandWales 2025-04-01 2026-03-31 12318994 2024-03-31 12318994 2025-03-31 12318994 2024-04-01 2025-03-31 12318994 frs-core:CurrentFinancialInstruments 2025-03-31 12318994 frs-core:ShareCapital 2025-03-31 12318994 frs-core:RetainedEarningsAccumulatedLosses 2025-03-31
Registered number: 12318994
Edgar AIC Ltd
Unaudited Financial Statements
For The Year Ended 31 March 2026
Contents
Page
Balance Sheet 1
Notes to the Financial Statements 2—4
Page 1
Balance Sheet
Registered number: 12318994
2026 2025
as restated
Notes £ £ £ £
FIXED ASSETS
Investments 4 1,334,664 1,334,664
1,334,664 1,334,664
CURRENT ASSETS
Debtors 5 2,207 1,802
2,207 1,802
Creditors: Amounts Falling Due Within One Year 6 (1,168,159 ) (1,185,855 )
NET CURRENT ASSETS (LIABILITIES) (1,165,952 ) (1,184,053 )
TOTAL ASSETS LESS CURRENT LIABILITIES 168,712 150,611
NET ASSETS 168,712 150,611
CAPITAL AND RESERVES
Called up share capital 7 10 10
Profit and Loss Account 168,702 150,601
SHAREHOLDERS' FUNDS 168,712 150,611
For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mrs L J Edgar
Director
1 September 2026
The notes on pages 2 to 4 form part of these financial statements.
Page 1
Page 2
Notes to the Financial Statements
1. General Information
Edgar AIC Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12318994 . The registered office is Hanover Buildings, 11-13 Hanover Street, Liverpool, Merseyside, L1 3DN.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
2.2. Financial Instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.
Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.
Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.
2.3. Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
2.4. Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
2.5. Consolidation
The company has taken advantage of the option not to prepare consolidated financial statements contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.
2.6. Registrar Filing Requirements
The company has taken advantage of Companies Act 2006 section 444(1) and opted not to file the profit and loss account, directors report, and notes to the financial statements relating to the profit and loss account.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 1 (2025: 1)
1 1
Page 2
Page 3
4. Investments
Unlisted
£
Cost or Valuation
As at 1 April 2025 1,334,664
As at 31 March 2026 1,334,664
Provision
As at 1 April 2025 -
As at 31 March 2026 -
Net Book Value
As at 31 March 2026 1,334,664
As at 1 April 2025 1,334,664
Subsidiary undertakings
The investment represents 100% of the issued ordinary share capital of Aura Infection Control Limited, a company registered in England and Wales. The registered office of Aura Infection Control Limited is Hanover Buildings, 11-13 Hanover Street, Liverpool, L1 3DN.
Aggregate capital and reserves as at 31 March 2026
Aura Infection Control Limited - £1,606,140
Profit for the year ended 31 March 2026
Aura Infection Control Limited - £672,874
Under the provision of section 398 of the Companies Act 2006 the company is exempt from preparing consolidated accounts and has not done so, therefore the accounts show information about the company as an individual entity.
5. Debtors
2026 2025
as restated
£ £
Due within one year
Other debtors 2,207 1,802
6. Creditors: Amounts Falling Due Within One Year
2026 2025
as restated
£ £
Amounts owed to group undertakings 1,094,812 939,645
Other creditors 73,347 246,210
1,168,159 1,185,855
7. Share Capital
2026 2025
as restated
£ £
Called Up Share Capital not Paid 10 10
Amount of Allotted, Called Up Share Capital 10 10
Page 3
Page 4
8. Directors Advances, Credits and Guarantees
No director received advances, credits or guarantees during the current or previous accounting periods.
9. Related Party Transactions
The following related party transactions were undertaken during the year:
A director introduced amounts totalling £30,170 (2025: £147,812 ) and withdrew amounts totalling £209,732 (2025: £315,213). At the balance sheet date the amount payable was £64,536 (2025: £244,098 ).
Aura Infection Control Limited is a subsidiary of the company. During the year the company received loans from the subsidiary totalling £256,752 (2025: £342,118) and made repayments totalling £95,000 (2025: £25,000). At the balance sheet date the amount payable to Aura Infection Control Limited was £1,101,397 (2025: £939,645).
Dividends were paid to the directors in respect of their shareholdings £30,170 (2025: £20,925).
The aggregate remuneration paid to key management personnel for the year was £Nil (2025: £Nil).
No further transactions with related parties were undertaken such as are required to be disclosed in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
Page 4